AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...
Amgen reported yesterday that full-year 2023 sales of Lumakras were $280 million, a dip on the prior year, while Mirati ... KRAS category comes shortly after AstraZeneca licensed a KRAS G12D ...
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.
A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers. Phase 1/2 ...
On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration ...
The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan ...
Silexion Therapeutics (SLXN ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback